Therapeutic potential of conopeptides

Future Medicinal Chemistry

Volumn 4, Issue 10, 2012, Pages 1243-1255

  Schroeder, Christina I ^a   Craik, David J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACV 1; ALPHA CONOTOXIN; CGX 1160; CHI CONOTOXIN; COMPLEMENTARY DNA; CONANTOKIN G; CONOPEPTIDE; CONOTOXIN; CYSTEINE; MU CONOTOXIN; NATURAL PRODUCT; OMEGA CONOTOXIN; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN MVIIA; UNCLASSIFIED DRUG; XEN 2174; ZENYTH;

BIOASSAY; CHRONIC PAIN; CLINICAL TRIAL (TOPIC); DIABETIC NEUROPATHY; DRUG DESIGN; DRUG MARKETING; EDMAN SEQUENCING; FRACTIONATION; GENOME; HERPES ZOSTER; HUMAN; ISCHIALGIA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR CLONING; NEUROPATHIC PAIN; PEPTIDE SYNTHESIS; PEPTIDOMICS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SEQUENCE ANALYSIS; SOLID PHASE SYNTHESIS; TRANSCRIPTOMICS;

ANIMALS; CLINICAL TRIALS AS TOPIC; CONOTOXINS; CONUS SNAIL; DRUG DESIGN; GENOMICS; NEURALGIA; OMEGA-CONOTOXINS; SOLID-PHASE SYNTHESIS TECHNIQUES; VENOMS;

EID: 84863889286     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.70     Document Type: Review

References (119)

1. Fotouhi N, Gillespie P, Goodnow R Jr. Lead generation. reality check on commonly held views. Exp. Opin. Drug Discov. 3(7), 733-744 (2008).
2. Dove A. Breaching the barrier. Nat. Biotech. 26(11), 1213-1215 (2008).
3. McGonigle P. Peptide therapeutics for CNS indications. Biochem. Pharmacol. 83(5), 559-566 (2012).
4. Wermeling DP. Ziconotide, an intrathecally administered N-Type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy 25(8), 1084-1094 (2005).
5. Labonte J, Lebbos J, Kirkpatrick P. Fresh from the pipeline: Enfuvirtide. Nat. Rev. Drug Discov. 2(5), 345-346 (2003).
6. Matthews T, Salgo M, Greenberg M, Chung J, Demasi R, Bolognesi D. Enfuvirtide. the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 3(3), 215-225 (2004).
7. Fineman MS, Bicask TA, Shen LZ et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26(8), 2370-2377 ( 2003).
8. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267(11), 7402-7405 (1992).
9. Khafagy E-S, Morishita M, Onuki Y, Takayama K. Current challenges in non-Invasive insulin delivery systems. A comparative review. Adv. Drug Del. Rev. 59(15), 1521-1546 (2007).
10. Eisenstein M. Something new under the skin. Nat. Biotechnol. 29, 107-109 (2011).
11. Henkin RI. Intranasal delivery to the brain. Nat. Biotechnol. 29, 480 (2011).
12. Henkin RI. Intranasal insulin. From nose to brain. Nutrition 26(6), 624-633 (2010).
13. Henkin RI. Inhaled insulin-Intrapulmonary, intranasal, and other routes of administration. mechanisms of action. Nutrition 26(1), 33-39 (2010).
14. Schroeder CI, Ekberg J, Nielsen KJ et al. Neuronally micro-Conotoxins from Conus striatus utilize an alpha-Helical motif to target mammalian sodium channels. J. Biol. Chem. 283(31), 21621-21628 (2008).
15. Green BR, Catlin P, Zhang MM et al. Conotoxins containing nonnatural backbone spacers. cladistic-Based design, chemical synthesis, and improved analgesic activity. Chem. Biol. 14(4), 399-407 (2007).
16. Robertson CR, Preuss TH, Grussendorf E, White HS, Bulaj G. Generating orally active galanin analogues with analgesic activities. ChemMedChem 7(5), 903-909 (2012
17. Sharpe IA, Gehrmann J, Loughnan ML et al. Two new classes of conopeptides inhibit the alpha1-Adrenoceptor and noradrenalin transporter. Nat. Neurosci. 4(9), 902-907 (2001).
18. Lovelace ES, Armishaw CJ, Colgrave ML et al. Cyclic MrIA. a stable and potent cyclic conotoxin with a novel topological fold that targets the norepinephrine transporter. J. Med. Chem. 49(22), 6561-6568 (2006).
19. Clark RJ, Jensen J, Nevin ST, Callaghan BP, Adams DJ, Craik DJ. The engineering of an orally active conotoxin for the treatment of neuropathic a pain. Angew. Chem. Int. Ed. Engl. 49(37), 6545-6548 (2010).
20. Armishaw CJ, Daly NL, Nevin ST, Adams DJ, Craik DJ, Alewood PF. α-Selenoconotoxins. A new class of potent α7 neuronal nicotinic receptor agonists. J. Biol. Chem. 281(20), 14136-14143 (2006).
21. De Araujo AD, Callaghan B, Nevin ST et al. Total synthesis of the analgesic conotoxin MrVIB through selenocysteine-Assisted folding. Angew. Chem. Int. Ed. Engl. 50(29), 6527-6529 (2011).
22. Chatterjee J, Laufer B, Kessler H. Synthesis of N-Methylated cyclic peptides. Nat. Protoc. 7(3), 432-444 (2012).
23. White TR, Renzelman CM, Rand AC et al. On-Resin N-Methylation of cyclic peptides for discovery of orally bioavailable scaffolds. Nat. Chem. Biol. 7(11), 810-817 (2011).
24. Craik DJ, Adams DJ. Chemical modifications of conotoxins to improve stability and activity. ACS Chem Biol 2(7), 457-468 (2007).
25. Kritzer JA. Stapled peptides. Magic bullets in nature's arsenal. Nat. Chem. Biol. 6(8), 566-567 (2010).
26. Walensky LD, Kung AL, Escher I et al. Activation of apoptosis in vivo by a hydrocarbon-Stapled BH3 helix. Science 305(5689), 1466-1470 (2004).
27. Ondetti MA, Williams NJ, Sabo EF, Pluscec J, Weaver ER, Kocy O. Angiotensin-Converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry 10(22), 4033-4039 (1971).
28. Ondetti MA. Structural relationships of angiotensin converting-Enzyme inhibitors to pharmacologic activity. Circulation 77(6 Pt 2), I74-78 (1988).
29. Cushman DW, Ondetti MA. Design of angiotensin converting enzyme inhibitors. Nat. Med. 5(10), 1110-1113 (1999).
30. Terlau H, Olivera BM. Conus venoms. A rich source of novel ion channel-Targeted peptides. Physiol. Rev. 84(1), 41-68 (2004).
31. Olivera BM, Teichert RW. Diversity of the neurotoxic Conus peptides. A model for concerted pharmacological discovery. Mol. Interv. 7(5), 251-260 (2007).
32. Halai R, Craik DJ. Conotoxins. natural product drug leads. Nat. Prod. Rep. 26(4), 526-536 (2009).
33. Schroeder CI, Lewis RJ. ω-Conotoxins GVIA, MVIIA and CVID. SAR and clinical potential. Mar. Drugs 4(3), 193-214 (2006).
34. Daly NL, Rosengren KJ, Henriques ST, Craik DJ. NMR and protein structure in drug design: Application to cyclotides and conotoxins. Eur. Biophys. J. 40(4), 359-370 (2011).
35. Mcintosh JM, Jones RM. Cone venom-From accidental stings to deliberate injection. Toxicon 39(10), 1447-1451 (2001).
36. Schroeder CI, Doering CJ, Zamponi GW, Lewis RJ. N-Type calcium channel blockers: Novel therapeutics for the treatment of pain. Med. Chem. 2(5), 535-543 (2006).
37. Norton RS, Olivera BM. Conotoxins down under. Toxicon 48(7), 780-798 (2007).
38. Lewis RJ. Conotoxins. molecular and therapeutic targets. Prog. Mol. Subcellular Biol. 46, 45-65 (2009).
39. Lewis RJ, Garcia MG. Therapeutic potential of venom peptides. Nat. Rev. Drug Disc. 2, 790-802 (2003).
40. Twede VD, Miljanich G, Olivera BM, Bulaj G. Neuroprotective and cardioprotective conopeptide: An emerging class of drug leads. Curr. Opin. Drug Discov. Devel. 12(2), 231-239 (2009).
41. Davis J, Jones A, Lewis RJ. Remarkable inter-And intra-Species complexity of conotoxins revealed by LC-MS. Peptides 30(7), 1222-1227 (2009).
42. Olivera BM. Conus peptides. biodiversity-Based discovery and exogenomics. J. Biol. Chem. 281(42), 31173-31177 (2006).
43. Kaas Q, Westermann J-C, Halai R, Wang CKL, Craik DJ. ConoServer, a database for conopeptide sequences and structures. Bioinformatics 24(3), 445-446 (2008).
44. Kaas Q, Westermann J-C, Craik DJ. Conopeptide characterization and classifications. An analysis using ConoServer. Toxicon 55(8), 1491-1509 (2010).
45. Olivera BM, Mcintosh JM, Cruz LJ, Luque FA, Gray WR. Purification and sequence of a presynaptic peptide toxin from Conus geographus venom. Biochemistry 23(22), 5087-5090 (1984).
46. Pallaghy PK, Nielsen KJ, Craik DJ, Norton RS. A common structural motif incorporating a cystine knot and a triple- stranded beta-Sheet in toxic and inhibitory polypeptides. Prot. Sci. 3(10), 1833-1839 (1994).
47. Craik DJ, Daly NL, Waine C. The cystine motif in toxins and implications for drug design. Toxicon 39(1), 43-60 (2001).
48. Wang YX, Bezprozvannaya S, Bowersox SS et al. Peripheral versus central potencies of N-Type voltage-Sensitive calcium channel blockers. Naunyn Schmiedebergs Arch. Pharmacol. 357(2), 159-168 (1998).
49. Sato K, Raymond C, Martin-Moutot N et al. Binding of chimeric analogs of omega-Conotoxin MVIIA and MVIIC to the N- and P/Q-Type calcium channels. FEBS Lett. 414(2), 480-484 (1997).
50. Kristipati R, Nadasdi L, Tarczy-Hornoch K et al. Characterization of the binding of omega-Conopeptides to different classes of non-L-Type neuronal calcium channels. Mol. Cell. Neurosci. 5(3), 219-228 (1994).
51. Cruz LJ, Olivera BM. Calcium channel antagonists. Omega-Conotoxin defines a new high affinity site. J. Biol. Chem. 261(14), 6230-6233 (1986).
52. + channels. Neuron 9(1), 69-77 (1992).
53. Lewis RJ, Nielsen KJ, Craik DJ et al. Novel omega-Conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J. Biol. Chem. 275(45), 35335-35344 (2000).
54. Nicke A, Wonnacott S, Lewis RJ. α-Conotoxins as tools for the elucidation of structure and function of neuronal nicotinic acetylcholine receptor subtypes. Eur. J. Biochem. 271(12), 2305-2319 (2004).
55. Gehrmann J, Alewood PF, Craik DJ. Structure determination of the three disulfide bond isomers of alpha- conotoxin GI. a model for the role of disulfide bonds in structural stability. J. Mol. Biol. 278(2), 401-415 (1998).
56. Mcintosh JM, Santos AD, Olivera BM. Conus peptides targeted to specific nicotinic acetylcholine receptor subtypes. Annu. Rev. Biochem. 68, 59-88 (1999).
57. Clark RJ, Akcan M, Kaas Q, Daly NL, Craik DJ. Cyclization of conotoxins to improve their biopharmaceutical properties. Toxicon 59(4), 446-455 (2012).
58. Hu H, Bandyopadhay PK, Olivera BM, Yandell M. Characterization of the Conus bullatus genome and its venom-Duct transcriptome. BMC Genomics 12, 60-74 (2011).
59. Toyohara J, Hashimoto K. Alpha7 nicotinic receptor agonists. potential therapeutic drugs for treatment of cognitive impairments in Schizophrenia and Alzheimer's Disease. Open Med. Chem. J. 4, 37-56 (2010).
60. Slotkin TA, Seidler FJ. Cholinergic receptor subtypes in the olfactory bulbectomy model of depression. Brain Res. Bull. 68(5), 341-345 (2006).
61. Quik M, Bordia T, O'Leary K. Nicotinic receptors as CNS targets for Parkinson's disease. Biochem. Pharm. 74(8), 1224-1234 (2007).
62. Vincler M, Wittenauer S, Parker R, Ellison M, Olivera BM, Mcintosh JM. Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 nicotinic acetylcholine receptors. Proc. Natl Acad. Sci. USA 103(47), 17880-17884 (2006).
63. Clark RJ, Fisher H, Dempster L et al. Engineering stable peptide toxins by means of backbone cyclization. stabilization of the alpha-Conotoxin MII. Proc. Natl Acad. Sci. USA 102(39), 13767-13772 (2005).
64. Halai R, Callaghan B, Daly NL, Clark RJ, Adams DJ, Craik DJ. Effects of cyclization on stability, structure, and activity of α-Conotoxin RgIA at the α9α10 nicotinic acetylcholine receptor and GABA(B) receptor. J. Med. Chem. 54(19), 6984-6992 (2011).
65. Armishaw CJ, Jensen AA, Balle LD, Scott KCM, Sorensen L, Stromgaard K. Improving the stability of α-Conotoxin AuIB through N-To-C cyclization. The effect of linker length on stability and activity at nicotinic acetylcholine receptor. Antiox. Red. Sign. 14(1), 65-76 (2011).
66. Lovelace ES, Gunasekera S, Alvarmo C et al. Stabilization of α-Conotoxin AuIB. Influences of disulfide connectivity and backbone cyclization. Antioxid. Redox Signal. 14(1), 87-95 (2011).
67. Sharpe IA, Palant E, Schroeder CI et al. Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-Activity relationship. J. Biol. Chem. 278(41), 40317-40323 (2003).
68. Cruz LJ, Gray WR, Olivera BM et al. Conus geographus toxins that discriminate between neuronal and muscle sodium channels. J. Biol. Chem. 260(16), 9280-9288 (1985).
69. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-Function relationships of voltage-Gated sodium channels. Pharmacol. Rev. 57(4), 397-409 (2005).
70. Wood JN, Boorman J. Voltage-Gated sodium channel blockers; target validation and therapeutical potential. Curr. Topics Med. Chem. 5(6), 529-537 (2005).
71. Bulaj G, West PJ, Garrett JE et al. Novel conotoxins from Conus striatus and Conus kinoshitai selectively block TTX-Resistant sodium channels. Biochemistry 44(19), 7259-7265 (2005).
72. Zhang MM, Green BR, Catilin P et al. Structure/function characterization of micro-Conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J. Biol. Chem. 282(42), 30699-30706 (2007).
73. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. Sodium channels in normal and pathological pain. Ann. Rev. Neursci. 33, 325-347 (2010).
74. Terlau H, Stocker M, Shon KJ, Mcintosh JM, Olivera BM. MicroO-Conotoxin MrVIA inhibits mammalian sodium channels, but not through site I. J. Neurophysiol. 76(3), 1423-1429 (1996).
75. Daly NL, Ekberg JA, Thomas L, Adams DJ, Lewis RJ, Craik DJ. Structures of μO-Conotoxins from Conus marmoreus. Inhibitors of tetrodotoxin (TTX)-Sensitive and TTX-Resistant sodium channels in mammalian sensory neurons. J. Biol. Chem. 279(24), 25774-25782 (2004).
76. Ekberg J, Jayamanne A, Vaughan CW et al. μO-Conotoxin MrVIB selectively blocks Nva1.8 sensory neuron specific sodium channels and chronic pain behaviour without motor deficits. Proc. Natl Acad. Sci. USA 103(45), 17030-17035 (2006).
77. Bulaj G, Zhang MM, Green BR et al. Synthetic μO-Conotoxin MrVIB blocks TTX-Resistant sodium channel Nav1.8 and has a long-lasting analgesic activity. Biochemistry 45(23), 7404-7414 (2006).
78. Olivera BM, Cruz LJ, De Santos V et al. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-Conotoxin from Conus magus venom. Biochemistry 26(8), 2086-2090 (1987).
79. Bowersox S, Mandema J, Tarcy-Hornoch K, Miljanich G, Luther RR. Pharmacokinetics of SNX-111, a selective N-Type calcium channel blocker, in rats and cynomolgus monkeys. Drug Metab. Dispos 25(3), 379-383 (1997).
80. Bowersox SS, Luther RR. Pharmacotherapeutic potential of omega-Conotoxin MVIIA (SNX-111), an N-Type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon 36(11), 1651-1658 (1998).
81. Scott D, Wright C, Angus J. Actions of intrathecal omega-Conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur. J. Pharmacol. 451(3), 279-286 (2002).
82. Smith MT, Cabot PJ, Ross FB, Robertson AD, Lewis RJ. The novel N-Type calcium channel blocker, AM336, produces potent dose-Dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 96(1-2), 119-127 (2002).
83. Nielsen CK, Lewis RJ, Alewood D et al. Anti-Allodynic efficacy of the chi-Conopeptide, Xen2174, in rats with neuropathic pain. Pain 118(1-2), 112-124 (2005).
84. Brust A, Palant E, Crocker DE et al. chi- Conopeptide pharmacophore development. toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain. J. Med. Chem. 52(22), 6991-7002 (2009).
85. Lewis RJ. Discovery and development of the χ-Conopeptide class of analgesic peptides. Toxicon 59(4), 524-528 (2012).
86. Sandall DW, Satkunanathan N, Keays DA et al. A novel alpha-Conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. Biochemistry 42(22), 6904-6911 (2003).
87. Satkunanathan N, Livett BG, Gayler KR, Sandall D, Down J, Khalil Z. Alpha-Conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones. Brain Res. 1059(2), 149-158 (2005
88. Livett BG, Sandall DW, Keays D et al. Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor. Toxicon 48(7), 810-829 (2006).
89. Nevin ST, Clark RJ, Klimis H, Christie MJ, Craik DJ, Adams DJ. Are alpha9alpha10 nicotinic acetylcholine receptors a pain target for alpha-Conotoxins? Mol. Pharmacol. 72(6), 1406-1410 (2007).
90. Callaghan B, Haythornthwaite A, Berecki G, Clark RJ, Craik DJ, Adams DJ. Analgesic alpha-Conotoxins Vc1.1 and Rg1A inhibit N-Type calcium channels in rat sensory neurons via GABAB receptor activation. J. Neurosci. 28(43), 10943-10951 (2008).
91. Adams DJ, Callaghan B, Berecki G. Analgesic conotoxins. block and G-Protein coupled receptor modulation of the N-Type (Ca(v)2.2) calcium channels. Br. J. Pharm. 16(2), 486-500 (2012).
92. Menez A, Stöcklin R, Mebs D. 'Venomics' or. The venomous systems genome project. Toxicon 47(3), 255-259 (2006).
93. Skjaerbaek N, Nielsen KJ, Lewis RJ, Alewood PF, Craik DJ. Determination of the solution structures of conantokin-G and conantokin-T by CD and NMR spectroscopy. J. Biol. Chem. 272(4), 2291-2299 (1997).
94. Scanlon MJ, Naranjo D, Thomas L, Alewood PF, Lewis RJ, Craik DJ. Solution structure and proposed binding mechanism of a novel potassium channel toxin kappa-Conotoxin PVIIA. Structure 5(12), 1585-1597 (1997).
95. Nicke A, Loughnan ML, Millard EL et al. Isolation, structure, and activity of GID, a novel alpha 4/7-Conotoxin with an extended N-Terminal sequence. J. Biol. Chem. 278(5), 3137-3144 (2003).
96. Jimenez EC, Olivera BM. Divergent M- and O-Superfamily peptides from venom of fish-Hunting Conus parius. Peptides 31(9), 1678-1683 (2010).
97. Dutertre S, Biass D, Stöcklin R, Favreau P. Dramatic intraspecimen variations within the injected venom of Conus consors. An unsuspected contribution to venom diversity. Toxicon 55(8), 1453-1462 (2010).
98. Tayo LL, Lu B, Cruz LJ, Yates JRR. Proteomic analysis provides insights on venom processing in Conus textile. J. Proteome Res. 9(5), 2292-2301 (2010).
99. Kauferstein S, Porth C, Kendel Y et al. Venomic study on cone snails (Conus spp.) from South Africa. Toxicon 57(1), 28-34 (2011).
100. Biass D, Dutertre S, Gerbault A et al. Comparative proteomic study of the venom of the piscivorous cone snail Conus consors. J. Proteomics 72(2), 210-218 (2009).
101. Zhang MM, Fiedler B, Green BR et al. Structural and functional diversity among μ-Conotoxins targeting TTX-Resistant sodium channels. Biochemistry 45(11), 3731-3840 (2006).
102. Craig AG, Bandyopadhyay P, Olivera BM. Post-Translationally modified neuropeptides from Conus venoms. Eur. J. Biochem. 264(2), 271-275 (1999).
103. Jakubowski JA, Sweedler JV. Sequencing and mass profiling highly modified conotoxins using global reductions/alkylation followed by mass spectrometry. Anal. Chem. 76(22), 6541-6547 (2004).
104. Jakubowski JA, Kelley WP, Sweedler JV. Screening for post-Translational modifications in conotoxins using liquid chromatography/ mass spectrometry. an important component of conotoxin discovery. Toxicon 47(6), 688-699 (2006).
105. Biggs JS, Olivera BM, Kantor YI. Alpha-Conopeptides specifically expressed in the salivary gland of Conus pulicarius. Toxicon 51(1), 101-105 (2008).
106. Santos AD, Mcintosh JM, Hilyard DR, Cruz LJ, Olivera BM. The A-Superfamily of cootoxins. structural and functional divergence. J. Biol. Chem. 279(17), 17596-17606 (2004).
107. Twede VD, Teichert RW, Walker CS et al. Conantokin-Br from Conus brettinghami and selectivty determinants for the NR2D subunit of the NMDA receptor. Biochemistry 48(19), 4063-4073 (2009).
108. Walker CS, Steel D, Jacobsen RB et al. The T-Superfamily of conotoxins. J. Biol. Chem. 274(43), 30664-30671 (1999).
109. Morin R, Bainbridge M, Fejse A et al. Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-Read sequencing. Biotechniques 45(1), 81-94 (2008).
110. Terrat Y, Biass D, Dutertre S et al. High-Resolution picture of a venom gland transcriptome: Case study with the marine snail Conus consors. Toxicon 59, 34-46 (2012).
111. Leipold E, Markgraf R, Schirmeyer J, Hartley O, Heinemann SH. XEP-018. Structure-Function studies. Presented at: Conodays-Celebrating CONCO. Zermatt, Switzerland 7-9 December 2011
112. Church DJ, Pennington M, Mebs D et al. Update in CONCO peptide partnering and development. Presented at: Conodays-Celebrating CONCO. Zermatt, Switzerland 7-9 December 2011
113. Consortium U. Ongoing and future developments at the Universal Protein resource. Nucleic Acid Res. 39, D214-D219 (2011).
114. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Sayers EW. GenBank. Nucleic Acids Res. 39, D32-D37 (2011).
115. Rose PW, Beran B, Bi C et al. The RCSB Protein Data Bank. Redesigned web site and web services. Nucleic Acids Res. 39, D392-D401 (2011).
116. Ulrich EL, Akutsu H, Doreleijers JF et al. BioMagResBank. Nucleic Acid Res. 36, D402-D408 (2008).
117. Kaas Q, Rilei Y, Jin A-H, Dutertre S, Craik DJ. ConoServer. updated content, knowledge, and discovery tools in the conopeptide database. Nucleic Acid Res. 40, D325-D330 (2012).
118. Muttenthaler M, Nevin ST, Grishin AA et al. Solving the alpha-Conotoxin folding problem. Efficient selenium-Directed on-Resin generation of more potent and stable nicotinic acetylcholine receptor antagonists. J. Am. Chem. Soc. 132(10), 3514-3522 (2010).
119. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4(3), 206-220 (2005)